China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the first nine months of 2024, showing a decrease in revenue and net profit compared to the previous year. Despite the decline, the company’s cash position improved significantly, ending the period with nearly 2 billion RMB in cash and cash equivalents. Investors are advised to interpret these results cautiously as they are unaudited and may be subject to adjustments.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
